Demant A/S shares rose 3.5% on the day after BofA Securities issued a double-upgrade, moving its recommendation from underperform to buy and increasing its price objective to DKK280 from DKK170. The rise in the target - a 64.7% increase - reflects the brokerage's view that multiple elements of Demant's investment case have meaningfully improved.
Analyst case laid out in three parts
BofA cited three reinforcing reasons for its action. First, channel checks by the bank suggested the global hearing-aid market expanded by roughly 5% in value terms in the first quarter of 2026. That pace, BofA said, already exceeds the 2-4% range most manufacturers, including Demant, expected for the full year.
Second, the brokerage highlighted faster-than-anticipated early uptake of the Oticon Zeal device. BofA estimated Zeal's serviceable addressable market at 3.81 million units and noted consensus assumptions imply a penetration rate below 2% - a gap the bank views as evidence of upside to current forecasts.
Third, the firm concluded the earnings-risk profile has improved. BofA increased its 2026 EPS forecast by 8.1% and its 2027 EPS forecast by 9.5%, while also lowering the cost-of-capital assumption it applies to the valuation. Together, these moves reflect the brokerage's assessment of reduced downside risk for Demant.
Market backdrop and immediate reaction
U.S. equities were mixed on the day - the S&P 500 rose 0.3%, the NASDAQ gained 0.9%, and the Dow Jones fell 0.2% - and BofA's note appeared to be the primary driver of the move in Demant stock rather than any major central bank decision or material macroeconomic surprise affecting European healthcare trading.
Following the note, Demant traded at DKK260.4, placing it below BofA's new DKK280 target and signaling that the market may be starting to incorporate the recovery scenario the bank outlined.
Sector context
Within the hearing-aid sector, Demant’s key rivals - GN, Sonova, and WS Audiology - collectively account for more than 90% of the global market alongside Demant. BofA's positive Q1 market-growth observation was compiled from results reported across all four of these major players, underscoring that the beat was broad-based within the dominant industry participants.
Analysts and investors responding to a high-conviction re-rating by a major brokerage, combined with above-consensus market data and a product cycle gathering momentum, were sufficient to push a meaningful re-pricing of Demant shares during the trading session.
What changed in the numbers
Key quantitative adjustments in BofA's work were explicitly tied to the upgrade: a 64.7% lift in the price objective from DKK170 to DKK280; an estimated Q1 market expansion of 5.4% that the bank cited as its view of quarter-on-quarter market growth; an Oticon Zeal serviceable addressable market estimate of 3.81 million units versus consensus that implies sub-2% penetration; and EPS increases of 8.1% for 2026 and 9.5% for 2027, together with a lower cost-of-capital assumption.
Bottom line
BofA's double-upgrade, underpinned by above-consensus market growth, encouraging early product traction, and an improved earnings-risk profile, was the proximate cause of Demant's intraday rally. With the stock trading near DKK260.4 and a fresh DKK280 price target in place, market participants appear to be beginning to price in the recovery trajectory that the brokerage now endorses.